Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey

Show full item record




Helin , T A , Zuurveld , M , Manninen , M , Meijers , J C M , Lassila , R & Brinkman , H J M 2018 , ' Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey ' , Transfusion , vol. 58 , no. 12 , pp. 3014-3026 . https://doi.org/10.1111/trf.14933

Title: Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey
Author: Helin, T. A.; Zuurveld, M.; Manninen, M.; Meijers, J. C. M.; Lassila, R.; Brinkman, H. J. M.
Contributor organization: HUSLAB
Department of Clinical Chemistry and Hematology
Department of Medicine
HUS Comprehensive Cancer Center
Date: 2018-12
Language: eng
Number of pages: 13
Belongs to series: Transfusion
ISSN: 1537-2995
DOI: https://doi.org/10.1111/trf.14933
URI: http://hdl.handle.net/10138/285686
Abstract: BACKGROUND: Uncontrollable bleeding is the leading cause of death in traumatically injured patients. The extent to which direct factor Xa inhibitors interfere with the applied resuscitation measures is presently unknown. STUDY DESIGN AND METHODS: In this study, we investigated the effect of the resuscitation fluid s saline, albumin, fresh frozen plasma (FFP) and solvent/ detergent (S/D)-treated plasma, fibrinogen concentrate, prothrombin complex concentrate (PCC), and combinations thereof on the hemostatic profile of rivaroxaban-anticoagulated whole blood and plasma. We used rivaroxaban-spiked whole blood and plasma from healthy donors, as well as plasma from patients on rivaroxaban, and mimicked a resuscitation approach in a 50% plasma dilution setting. Thromboelastography, thrombin generation, and fibrin generation clot lysis test were assessed using tissue factor to initiate coagulation and tissue plasminogen activator to induce clot lysis. RESULTS: Rivaroxaban resulted in a hypocoagulant state that remained largely unaltered upon subsequent 50% dilution with S/D-treated plasma or FFP. Using SID treated plasma as a diluent, clot stability decreased due to its low (12-antiplasmin. Dilution with saline and albumin induced a profibrinolytic state and further deteriorated the impaired hemostatic potential of rivaroxabananticoagulated blood, even after PCC and fibrinogen support. Combined use of plasma (either FFP or S/D treated) and PCC, however, considerably improved both coagulation and clot stability. CONCLUSION: In the setting of rivaroxaban anticoagulation and major blood loss, transfusing plasma together with PCC may provide the most effective resuscitation approach with the notion that additional antifibrinolytic drug support (e.g., tranexamic acid) is likely required.
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Usage restriction: closedAccess
Self-archived version: submittedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Riva_reversal_F ... OR_SUBMISSION_PREPRINT.pdf 531.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record